摘要
目的评价HCG和(或)β-HCG在睾丸精原细胞瘤中的临床价值。方法回顾性分析我院睾丸精原细胞瘤HCG和(或)β-HCG异常的11例及同期20例HCG和(或)β-HCG正常患者的临床资料。结果睾丸精原细胞瘤HCG异常与患者年龄、肿瘤侧别、原发肿瘤大小、隐睾病史无关。HCG正常组、HCG升高小于正常值100倍和升高大于正常值100倍患者中Ⅲ期的比例分别为5％(1/20)、11.1％(1/9)和100％(2/2)。手术联合放疗和(或)化疗,HCG正常组、HCG升高小于正常值100倍和升高大于正常值100倍患者的累积5年生存率分别为92％、100％和0％。结论睾丸精原细胞瘤HCG升高小于正常值100倍对预后无不良影响,但如HCG过度升高,可能预后不好。
Objective To evaluate the prognostic value of HCG/β- HCG in seminoma. Method The clinical records of 11 seminoma cases with elevated HCG/β- HCG and 20 cases with normal HCG/β- HCG in peripheral blood were retrospectively reviewed. Result The elevation of HCG/β- HCG was not associated with the age of patients, tumor size and the present of cryptorchidism. The proportion of stage Ⅲ/Ⅳ disease was 5% (1/20), 11.1% (1/9) and 100% (2/2) respectively for patients with normal HCG/β- HCG, those with elevated HCG/β- HCG less than 100 times and those with elevated HCG/β- HCG over 100 times of the upper limit of normal value. Treated with combined surgery, irra- diation and/or chemotherapy, the 5 - year accumulative survival rate was 92%, 100% and 0% for patients with normal HCG/β- HCG, those with elevated HCG/β- HCG less than 100 times and those with elevated HCG/β- HCG over 100 times of the upper limit of normal value respec- tively. Conclusion An elevation of HCG/β- HCG less than 100 times of the upper limit of normal value is not an unfavorable prognostic factor in pure seminoma. However, extremely elevated HCG/β- HCG may be has an adverse impact on outcome.
出处
《医学研究通讯》
2004年第8期8-10,共3页
Bulletin of Medical Research
